BIODESIX INC
For the period ended Feb 26, 2026. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Feb 26, 2026 · Filed Feb 26, 2026
Use the contents to explore the available documents and sections.
BDSX$8.53-57.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except per share data)
(in thousands, except per share data)
| Three Months Ended December 31, | Year Ended December 31, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues | ||||
| Diagnostic Tests | $25,148 | $17,205 | $79,197 | $64,708 |
| Development Services | 3,607 | 3,224 | 9,302 | 6,615 |
| Total revenues | 28,755 | 20,429 | 88,499 | 71,323 |
| Direct costs and expenses | 4,879 | 4,342 | 16,719 | 15,573 |
| Research and development | 2,870 | 2,414 | 12,001 | 9,559 |
| Sales, marketing, general and administrative | 22,972 | 20,219 | 87,545 | 80,451 |
| Impairment loss on intangible assets | 1 | 103 | 107 | 238 |
| Total operating expenses | 30,722 | 27,078 | 116,372 | 105,821 |
| Loss from operations | (1,967) | (6,649) | (27,873) | (34,498) |
| Other (expense) income: | ||||
| Interest expense | (2,059) | (1,752) | (7,716) | (8,258) |
| Loss on extinguishment of liabilities | — | — | — | (248) |
| Change in fair value of warrant liability, net | — | — | (280) | — |
| Other income, net | 46 | 150 | 604 | 73 |
| Total other expense | (2,013) | (1,602) | (7,392) | (8,433) |
| Net loss | $(3,980) | $(8,251) | $(35,265) | $(42,931) |
| Net loss per share, basic and diluted | $(0.49) | $(1.13) | $(4.67) | $(6.64) |
| Weighted-average shares outstanding, basic and diluted | 8,065 | 7,330 | 7,551 | 6,470 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.